Form 4: Aquestive Therapeutics Executive Peter E. Boyd Reports Stock and Option Awards

Peter E. Boyd, an executive at Aquestive Therapeutics, reported the acquisition of restricted stock and stock options, along with a correction to a previous filing regarding shares beneficially owned.

Summary

• On March 7, 2024, Peter E. Boyd, SVP at Aquestive Therapeutics, reported the acquisition of 86,250 shares of common stock and 43,125 non-qualified stock options.
• The common stock is represented by restricted stock vesting in three annual installments: 25% on the first and second installments, and 50% on the third.
• The stock options, with an exercise price of $5.68, also vest in three annual installments with the same vesting schedule as the restricted stock and expire on 03/07/2034.
• An amendment was made to a previous Form 4 filing from March 9, 2023, to correct an administrative error regarding the number of shares beneficially owned, increasing the reported amount by 216 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily reports transactions related to executive compensation. The correction of an administrative error is a minor positive for transparency.

Positives

• The granting of restricted stock and stock options to an executive could be seen as an incentive to align their interests with the company's long-term success.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.

Stakeholder Impact

• The granting of stock options and restricted stock can align the interests of management with those of shareholders.

Key Dates